Trial Profile
A Phase 1a/1b Study of SBP-101 in Previously Treated Subjects with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2021
Price :
$35
*
At a glance
- Drugs Ivospemin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors Panbela Therapeutics
- 27 Jul 2018 According to Sun BioPharma media release a poster reviewing the results of this phase I safety study presented at the PancreasFest in Pittsburgh, PA.
- 05 Jun 2018 Results (n=29) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 14 May 2018 According to a Sun BioPharma media release, Study data were reviewed by the principal investigators and Data Safety Monitoring Board and submitted to the American Society for Clinical Oncology (ASCO). An abstract was accepted for online publication in the 2017 Annual Clinical Proceedings on May 16, 2018